Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

TNYA 01.13.2025

Full Press ReleaseSEC FilingsOur TNYA Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones
  • 12.17.2024 - MyPEAK-1 Phase 1b/2 Initial Results
  • 12.17.2024 - Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Recent Filings

  • 12.17.2024 - 8-K Current report
  • 12.17.2024 - EX-99.1 EX-99.1
  • 11.18.2024 - 4 Statement of changes in beneficial ownership of securities
Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com